Supply Chain Intelligence

Rigel Pharmaceuticals, Inc. Supply Chain

RIGL supply chain intelligence for Rigel Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

RIGL ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

8Suppliers
21Customers
1Debt Items
20Related Chains

Source-Backed Evidence Depth

Rigel Pharmaceuticals, Inc. (RIGL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

31Total relationships
4Distinct source URLs
12High confidence
0.756Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Rigel Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
ARVINAS-ESTROGEN-RECEPTOR-INC ARVINAS-ESTROGEN-RECEPTOR-INC 90% Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
ARVINAS-INC ARVINAS-INC 90% Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
ARVINAS-OPERATIONS-INC ARVINAS-OPERATIONS-INC 90% Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
PFIZER-INC PFIZER-INC 85% In connection with the transition of the Licensed Products, Pfizer will continue to be responsible for certain ongoing development activities, and Rigel has agreed to reimburse the Licensors for cert…
CRIS Curis, Inc. 72% Reciprocal relationship from CRIS graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from CRIS g…
HCM HUTCHMED (China) Limited 72% Reciprocal relationship from HCM graph: ber 14, 2021 to set aside the final award which was heard by the High Court in Hong Kong on June 28, 2022 and dismissed by the judge on July 26, 2022. Luye obt…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: nt assistance programs. Numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing…
ORANY ORANY 72% nt assistance programs. Numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing litigation, enforcement activities and settlements related to their patient suppor…

Rigel Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
CENCORA-INC CENCORA-INC 90% Three Months Ended March 31, 2026 2025 Cencora, Inc. 23 % 20 %
OPTIME-CARE-INC OPTIME-CARE-INC 90% Three Months Ended March 31, 2026 2025 Optime Care, Inc. ^ — % 11 %
CAH Cardinal Health, Inc. 85% ivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the balance sheet. The foll…
CAH Cardinal Health, Inc. 85% Reciprocal relationship from CAH graph: Reciprocal relationship from RIGL graph: ivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to cer…
MCK McKesson Corporation 85% Reciprocal relationship from MCK graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from MCK graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from MCK grap…
MCK McKesson Corporation 85% onouncements For a discussion of recent accounting pronouncements, see “Note 1– Description of Business and Summary of Significant Accounting Policies”, in the “Notes to Financial Statements” contain…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from RIGL graph: al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or…
LLY Eli Lilly and Company 72% al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, then the distribution of our products may be…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from ORAN…
ORANY ORANY 72% nd incident reporting requirements on ‘essential’ and ‘important’ entities, which include ICT managed service providers (MSP), cloud service providers as well as entities carrying out research and de…
SNYNF Sanofi 72% al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, then the distribution of our products may be…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from RIGL graph: al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections …
VOR Vor Biopharma Inc. 72% Reciprocal relationship from VOR graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from VOR graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from VOR grap…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% ions, including that the products are from countries that have entered into trade agreements with the US or meet an urgent public health need. Each of our three commercial products has received orpha…
HEALTH-RESOURCES HEALTH-RESOURCES 62% FDA can require and could negatively affect prescribing rates, patient willingness to initiate or continue 51 Table of Contents therapy, and payer coverage and reimbursement for GAVRETO. If the box w…
JW-PHARMACEUTICAL-CORPORATION JW-PHARMACEUTICAL-CORPORATION 62% s in the revenue derived from the sale of TAVALISSE and thereby materially harm our business and financial condition. TAVALISSE Commercial activities, including sales and marketing Our marketing and …
KISSEI-PHARMACEUTICAL-CO-LTD KISSEI-PHARMACEUTICAL-CO-LTD 62% y 1, 2026 $ 12,519 $ 10,389 $ 4,808 $ 27,716 Provision related to current period sales 14,379 4,766 550 19,695 Adjustment related to prior period sales ( 363 ) ( 381 ) — ( 744 ) Credit or payments ma…
MEDISON-PHARMA-LTD MEDISON-PHARMA-LTD 62% y 1, 2026 $ 12,519 $ 10,389 $ 4,808 $ 27,716 Provision related to current period sales 14,379 4,766 550 19,695 Adjustment related to prior period sales ( 363 ) ( 381 ) — ( 744 ) Credit or payments ma…
MEDISON-PHARMA-TRADING-AG MEDISON-PHARMA-TRADING-AG 62% y 1, 2026 $ 12,519 $ 10,389 $ 4,808 $ 27,716 Provision related to current period sales 14,379 4,766 550 19,695 Adjustment related to prior period sales ( 363 ) ( 381 ) — ( 744 ) Credit or payments ma…
PATHOS-AI-INC PATHOS-AI-INC 62% ears of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), and…
RAIN-ONCOLOGY-INC RAIN-ONCOLOGY-INC 62% ears of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), and…

Rigel Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
RIGL-DEBT Debt stack $45.0M 90% Market cache reports total debt of $45.0M.

Rigel Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
RIGL-OWNER-QUINN-OPPORTUNITY-PARTNERS-LLC Quinn Opportunity Partners LLC 90% 13F overlay lists Quinn Opportunity Partners LLC as top holder; 13 tracked holders.

Rigel Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
AMPH Amphastar Pharmaceuticals, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ORANY ORANGE 100.00 1 ['customer', 'supplier']
NVO Novo Nordisk A/S 100.00 2
SDGR Schrödinger, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
BPTH Bio-Path Holdings, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
CVS CVS Health Corporation 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
CAH Cardinal Health, Inc. 100.00 1 ['customer']
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Rigel Pharmaceuticals, Inc..

Unlock full RIGL data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
RIGL
Unlock RIGL Supply Chain Data
Verified relationships include:
ARVINAS-ESTROGEN-RECEPTOR-INCARVINAS-ESTROGEN-RECEPTOR-INCSupplier90%
ARVINAS-INCARVINAS-INCSupplier90%
CENCORA-INCCENCORA-INCCustomer90%
OPTIME-CARE-INCOPTIME-CARE-INCCustomer90%
+27 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →